Examining the Use of Serum Biomarkers to Guide Early Detection of Pancreatic Cancer

Screening barriers involve a low incidence and histologic heterogeneity of disease, as well as a need for prospective multicenter analysis of proposed biomarkers. Because the poor prognosis of PDAC is attributed to late detection, the development of a clinical guideline for biomarker-based screening warrants interprofessional awareness and advocacy in oncology clinical practice.